Jardiance Cost in Montana 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Jardiance Cost in Montana in 2026?

The manufacturer list price for Jardiance (empagliflozin) sits at roughly $680 per month across Montana retail pharmacies in 2026, regardless of the dose strength (10 mg or 25 mg). That figure is a starting point, not what most patients actually pay. Your real out-of-pocket cost depends on insurance tier placement, prior authorization status, manufacturer savings programs, and whether you qualify for a compounded alternative.

Cash-paying patients at Montana pharmacies, including chains such as Albertsons and Walmart as well as independent rural pharmacies in Billings, Missoula, and Great Falls, will generally see prices clustered near that $680 mark before any discount card is applied. GoodRx and similar coupon platforms can reduce the retail price by 15 to 30 percent at select locations, bringing some quotes closer to $450 to $530 per month. Prices shift week to week as pharmacy contract negotiations change, so always run a real-time search at the pharmacy counter or on GoodRx before assuming a price is current.

The FDA-approved label for empagliflozin covers three distinct indications: glycemic control in adults with type 2 diabetes, reduction of cardiovascular death and hospitalization in adults with heart failure (both reduced and preserved ejection fraction), and slowing of kidney disease progression in adults with chronic kidney disease. [1] Each indication may be coded differently on an insurance claim, which means patients with heart failure or CKD sometimes face different formulary tiers than those with type 2 diabetes alone.

[1] Jardiance Prescribing Information. FDA. Accessed 2025.

Does Montana Medicaid Cover Jardiance?

Montana Medicaid does not cover brand-name Jardiance for most beneficiaries as of 2026. The Montana Department of Public Health and Human Services Medicaid Preferred Drug List places empagliflozin in a non-preferred or non-covered category for standard fee-for-service enrollees. This is a meaningful gap. Montana's Medicaid expansion covers roughly 100,000 low-income adults, many of whom carry diagnoses of type 2 diabetes or heart failure, the two conditions where empagliflozin shows the strongest mortality benefit.

Exceptions do exist. Patients with documented cardiovascular disease and prior authorization may receive case-by-case coverage, and managed care plans contracting with Montana Medicaid retain some flexibility to place empagliflozin on their own formularies. The practical advice for any Montana Medicaid enrollee: ask your prescriber to submit a prior authorization request citing the EMPA-REG OUTCOME trial data, which demonstrated a 38% relative reduction in cardiovascular mortality in adults with type 2 diabetes and established cardiovascular disease. [2]

If prior authorization is denied, the Boehringer Ingelheim patient assistance program (called myBI) provides free or reduced-cost Jardiance to uninsured or underinsured patients whose household income falls at or below 400% of the federal poverty level. Applications are processed through the prescriber's office.

[2] Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM. 2015;373:2117, 2128.

Is Compounded Empagliflozin Legal in Montana?

Compounded empagliflozin from a state-licensed 503A pharmacy is currently legal in Montana for patients with a valid prescription from a licensed prescriber. A 503A pharmacy compounds medications for individual patients based on a specific prescription. It operates under state pharmacy board oversight and, in Montana, the Board of Pharmacy enforces USP standards for compounded preparations.

This is a nuanced area of pharmacy law. The FDA has not placed empagliflozin on its "do not compound" list as of early 2025, and no federal shortage designation is required for 503A compounding of this molecule. That distinguishes empagliflozin from the GLP-1 receptor agonists (semaglutide, tirzepatide), which were compounded primarily because of documented FDA shortage status. Patients and prescribers should confirm that the compounding pharmacy they choose is licensed by the Montana Board of Pharmacy and operates under a valid state registration.

Compounded empagliflozin carries real cost advantages. Several telehealth platforms serving Montana patients quote compounded oral empagliflozin preparations at prices substantially below the $680 brand-name list price, and in some cases partner pharmacies absorb the drug cost within a membership model. Clinically, the compound must deliver bioequivalent amounts of the active ingredient, but because compounded preparations are not FDA-approved, bioequivalence testing is not required in the same way it is for generic manufacturers. Discuss this tradeoff explicitly with your prescriber.

Generic empagliflozin is not yet available in the United States as of early 2025. Lilly and Boehringer Ingelheim hold patents on Jardiance that do not expire until the late 2020s. When a true generic clears FDA approval, the compounding calculus will shift considerably.

How Does the Jardiance Savings Card Work in Montana?

The Boehringer Ingelheim and Eli Lilly co-pay savings card, marketed under the "Jardiance Savings Card" program, allows eligible commercially insured patients to pay as little as $10 per 30-day supply. Montana residents who have private insurance, employer-sponsored insurance, or Medicare Part D do not all qualify equally.

For commercially insured patients (private or employer plans), the savings card can reduce the co-pay to $10 per month, with a maximum annual savings cap that the manufacturer updates periodically. Patients should enroll at the official Jardiance website or through their prescriber's office. The card is processed at the pharmacy counter like a secondary insurance benefit.

Medicare Part D patients are explicitly excluded from the commercial savings card under federal anti-kickback statute provisions. Medicare enrollees in Montana should instead ask their Part D plan about coverage, check formulary tiers during the annual open enrollment window (October 15 to December 7), and inquire about the Medicare Extra Help (Low Income Subsidy) program if their income qualifies. Extra Help can reduce Part D cost-sharing substantially for eligible beneficiaries.

Uninsured patients are not eligible for the standard savings card either, but Boehringer Ingelheim's myBI patient assistance program fills that gap for income-qualifying individuals.

The HealthRX clinical team developed the following decision framework for Montana patients trying to find the lowest legal cost for empagliflozin:

Step 1. Confirm your insurance status. Commercial insurance with prior authorization approved is usually the lowest-cost path if you can satisfy the formulary criteria.

Step 2. If commercially insured and the savings card is active, your co-pay drops to $10 per month. Verify the current program terms directly with the manufacturer, as caps and eligibility rules change annually.

Step 3. If you are on Montana Medicaid, submit a prior authorization request before assuming the drug is inaccessible. Cardiovascular or CKD documentation strengthens the clinical case.

Step 4. If you are uninsured or underinsured and do not qualify for the savings card, apply to myBI patient assistance before assuming cash price is your only option.

Step 5. If you still face a prohibitive cost after steps 1 through 4, consult a licensed telehealth prescriber about compounded empagliflozin from a Montana Board of Pharmacy-licensed 503A pharmacy.

Step 6. Never purchase empagliflozin from an unlicensed online pharmacy. Several sites selling international generic equivalents operate outside FDA and Montana Board of Pharmacy jurisdiction, creating genuine safety and legal risks.

Which Insurance Plans Cover Jardiance in Montana?

Most major commercial insurers operating in Montana place Jardiance on their formulary, but the tier position varies. Blue Cross Blue Shield of Montana, PacificSource, and Mountain Health CO-OP all offer individual and group plans through the state exchange; formulary tiers for empagliflozin across these plans range from Tier 2 (preferred brand, lower co-pay) to Tier 3 or Tier 4 (non-preferred brand, higher cost-sharing). Tier position in a given year is visible on the plan's formulary tool during open enrollment.

Prior authorization (PA) is the most common barrier. Insurers typically require documentation of a type 2 diabetes diagnosis with HbA1c at or above a threshold (often 7.5% to 8.0%), or a confirmed diagnosis of heart failure or CKD with supporting labs. The prescriber submits a PA request; turnaround in Montana averages 3 to 5 business days for non-urgent requests.

Step therapy requirements are another barrier. Some Montana plans require the patient to try and fail metformin, a sulfonylurea, or sometimes another SGLT2 inhibitor (such as dapagliflozin or canagliflozin) before approving Jardiance specifically. If a clinical contraindication to those agents exists, the prescriber can request a step therapy exception. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as preferred agents in patients with type 2 diabetes and heart failure or CKD regardless of baseline HbA1c, which provides strong guideline language to support an exception request. [3]

[3] American Diabetes Association. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1).

Can I Get Jardiance via Telehealth in Montana?

Yes. Montana permits telehealth prescribing of Jardiance for established patient-provider relationships. Under Montana law (MCA 37-2-104 and subsequent guidance from the Montana Board of Medical Examiners), a prescriber may establish a patient-provider relationship using audio-visual telehealth and then prescribe Schedule V and non-controlled medications without an in-person visit. Empagliflozin is not a controlled substance, so it falls clearly within that scope.

Several telehealth platforms licensed to practice in Montana include empagliflozin in their cardiometabolic or diabetes medication formularies. A typical telehealth workflow: the patient completes an intake questionnaire and provides recent lab values (HbA1c, eGFR, urine albumin-to-creatinine ratio, and basic metabolic panel), a provider reviews the information in a synchronous or asynchronous visit, and a prescription is sent electronically to a Montana pharmacy or a partner compounding pharmacy.

The clinical workup matters. Empagliflozin is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 20 mL/min/1.73 m2 for glycemic indications, and dosing guidance for the CKD indication differs from the diabetes indication. Any prescriber, telehealth or in-person, should review renal function before initiating the drug and recheck it at least annually. The EMPA-KIDNEY trial (N=6,609) confirmed that empagliflozin 10 mg reduced the composite of kidney disease progression or cardiovascular death by 28% vs. placebo (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) in adults with CKD, further broadening the patient population who might benefit. [4]

[4] The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. NEJM. 2023;388:117, 127.

What Are the Clinical Benchmarks That Justify Jardiance's Cost?

The cost of Jardiance is frequently debated in value-based care conversations. For Montana prescribers and patients weighing whether the drug is worth $680 per month before discounts, the trial data provide concrete anchors.

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease across 42 countries. Patients randomized to empagliflozin (10 mg or 25 mg once daily) experienced a 14% relative risk reduction in the primary composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke compared with placebo (10.5% vs. 12.1%, HR 0.86 to 95% CI 0.74 to 0.99, P=0.04 for superiority). The cardiovascular death reduction alone was 38% (3.7% vs. 5.9%, HR 0.62). [2] These are hard endpoints, not surrogate markers.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% vs. placebo in patients with HFrEF (ejection fraction below 40%), with consistent benefit across diabetic and non-diabetic subgroups. [5] The EMPEROR-Preserved trial (N=5,988) then extended this to HFpEF. [6]

For a patient in Billings, Montana with type 2 diabetes and a recent heart failure hospitalization, these numbers translate to a medication that may prevent a repeat hospitalization costing $15,000 to $30,000, making the $680 monthly list price a different calculation than it appears at first glance. That does not make the cost acceptable for patients without assistance, but it anchors the discussion in outcomes rather than sticker price.

[5] Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. NEJM. 2020;383:1413, 1424.

[6] Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. NEJM. 2021;385:1451, 1461.

What Are the Side Effects and Safety Considerations Montana Patients Should Know?

Empagliflozin's mechanism, blocking renal glucose reabsorption via SGLT2, generates a predictable side-effect profile. Genital mycotic infections (yeast infections) are the most common adverse event, occurring in approximately 6% of women and 3% of men in clinical trials. Urinary tract infections occur at a similar background rate to placebo in most trials but can be clinically significant in older adults or patients with recurrent UTI history.

Diabetic ketoacidosis (DKA) is a rare but serious complication, particularly in patients who are fasting, undergoing surgery, or have unrecognized type 1 diabetes. The FDA added a black-box warning for this risk. Patients and prescribers in Montana should follow the standard guidance: hold empagliflozin at least 3 days before elective surgery or prolonged fasting.

Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported across the SGLT2 inhibitor class. The FDA issued a safety communication in 2018 based on 12 cases identified across all SGLT2 inhibitors, a small absolute number given millions of prescriptions, but the severity warrants patient education about early warning signs. [7]

Volume depletion and hypotension are relevant in elderly Montana patients or those on concurrent diuretics. Starting empagliflozin in a patient already on high-dose furosemide requires monitoring of blood pressure and renal function at 2 to 4 weeks.

[7] FDA Drug Safety Communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors. 2018.

How Does Empagliflozin Compare to Other SGLT2 Inhibitors Available in Montana?

Three SGLT2 inhibitors hold broad FDA approval and are commercially available in Montana: empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). A fourth, ertugliflozin (Steglatro), is approved for type 2 diabetes but has a smaller outcomes dataset.

Dapagliflozin has strong CKD evidence from DAPA-CKD (N=4,304), which showed a 39% relative risk reduction in the composite of sustained decline in eGFR, end-stage kidney disease, or death from renal or cardiovascular causes. [8] Canagliflozin has cardiovascular data from CREDENCE (N=4,401) focused specifically on diabetic kidney disease. The practical question for Montana prescribers and insurance navigators is formulary placement. On some Montana Blue Cross plans, dapagliflozin occupies a preferred tier while empagliflozin sits one tier higher, which can shift the math entirely. Ask your prescriber to check the formulary before writing the prescription rather than after.

The 2024 ADA Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, heart failure, or chronic kidney disease, an SGLT2 inhibitor with evidence for the relevant complication is recommended." [3] That language does not specify a single agent, giving prescribers flexibility to choose the one that fits the patient's formulary and renal function profile.

[8] Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. NEJM. 2020;383:1436, 1446.

What Practical Steps Should Montana Patients Take Right Now?

For a Montana patient facing a $680 monthly price at the pharmacy counter, four concrete actions apply immediately.

First, confirm whether your insurer requires prior authorization and whether your diagnosis code qualifies. Type 2 diabetes alone, heart failure alone, and CKD each map to different coverage pathways.

Second, apply for the manufacturer savings card the same day your prescription is written if you have commercial insurance. The activation typically takes minutes online and can be used at first fill.

Third, if you are on Montana Medicaid and the standard PDL excludes Jardiance, ask your provider to submit a PA with the EMPA-REG OUTCOME cardiovascular mortality data (38% reduction in CV death) [2] and your most recent echo or eGFR as supporting documentation. Documented cardiovascular disease or CKD stages G3 to G4 strengthens the case.

Fourth, if you remain uninsured or cost-prohibited after the above steps, consult a telehealth provider licensed in Montana about compounded empagliflozin from a 503A pharmacy. Confirm the pharmacy's Montana Board of Pharmacy registration number before dispensing. The starting dose for type 2 diabetes is 10 mg orally once daily, titrated to 25 mg once daily if tolerated and additional glycemic control is needed. For heart failure and CKD indications, 10 mg once daily is the studied and labeled dose.